EP 1043
Alternative Names: EP-1043; Recombinant protein vaccine EP-1043Latest Information Update: 02 Oct 2021
At a glance
- Originator Pharmexa-Epimmune
- Developer National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention) in Peru (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention) in USA (Parenteral, Injection)
- 09 Nov 2007 A phase I trial in HIV-1 infections (HVTN 064) has been completed